[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560389":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sarcoidosis patients",null,"This study only consists of one arm. The investigators follow patients prospectively and observe clinical parameters including disease course (resolving, non-resolving, which organs are involved, inflammatory markers, chest X-ray etc) and effect of treatment. In this respect the study is observational. However, the patients undergo repeated peripheral blood samples and some also undergo sampling from upper airways, faeces and a bronchoscopy and hence, the study falls in the interventional category",[13],"Procedure: peripheral blood sampling, bronchoscopy, upper airway and faeces sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","peripheral blood sampling, bronchoscopy, upper airway and faeces sampling","1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml\u002Fyear but never more than 100 ml\u002F month.\n2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times\u002Fyear.\n3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times\u002Fyear.\n4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment.",[9],[21],{"name":22,"affiliation":23,"role":24},"Susanna M Kullberg, MD","Karolinska University Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","070-2715639","+46","susanna.kullberg@regionstockholm.se",[32],{"facility":23,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Stockholm","Stockholm County","171 76","Sweden","SE",{"type":40,"coordinates":41},"Point",[42,43],18.06871,59.32938,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":28,"phoneExt":29,"email":30},"Susanna Kullberg, MD",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51],{"name":52,"class":53},"Karolinska Institutet","OTHER","100560389","immunological-mechanisms-in-sarcoidosis-100560389",false,"NCT06576505","Immunological Mechanisms in Sarcoidosis","Immunologiska Mekanismer Vid Sarkoidos","Inclusion Criteria:\n\n* Suspicion of sarcoidosis\n* Swedish speaking\n* Able to understand and approve of study protocol\n* No contraindications for planned interventions\n* For inclusion of healthy controls they need to be healthy and the same criteria as listed above for patients.\n\nExclusion Criteria:\n\n* No suspicion of sarcoidosis\n* Not Swedish-speaking\n* Not able to understand study protocol\n* Not approving of study protocol\n* Contraindications for planned interventions",true,"ALL","18 Years","90 Years",{"count":66,"type":67},5000,"ESTIMATED","OBSERVATIONAL","There is no cure for the inflammatory disease sarcoidosis. Virtually any part of the body can be affected but most often the lungs and lymph nodes. Outcomes after diagnosis vary widely among sarcoidosis patients, with some experiencing resolving disease and others developing chronic disease and lung fibrosis. Cardiac sarcoidosis can lead to life threatening arrythmias and calcium metabolism disturbances can lead to renal impairment.\n\nTreatment with different forms of immunosuppressants are usually tried to dampen symptoms but are not effective in all patients. Furthermore, the disease usually flares up after cessation of treatment. The variability in diseae course and treatment response is thought, at least to some degree, to be explained by individual differences in genetics, immune cells and signaling pathways. But existing evidence is limited. In other inflammatory diseases the gut microbiome is of importance for disease course but its role in sarcoidosis has not been clarified.\n\nIn this prospective project the investigators will study genes, inflammatory cells and signaling molecules in the lung, upper airways and blood, and to some extent microbes, also in faeces. Healthy volunteers will be included for comparative studies. Most samples will be taken during normal diagnostic work-up and follow-up of patients with\u002Fwith suspected sarcoidosis. The findings will be correlated to disease course and effects of different treatments. By linking to national health data and demographic registries, comorbidities and environmental factors will be correlated to data.\n\nBy this, the investigators hope to improve understanding of which genes, cells and signaling molecules that are of importance for resolving vs non-resolving disease and why some patients respond to a certain treatment and others don´t. The overall goal is to assess and predict sarcoidosis outcomes. We hypothesize that blood-based biomarkers including those taken during routine care as well as novel cell, signaling molecules and genetic markers, in combination with clinical characteristics can be used to predict outcomes, also treatment response, in sarcoidosis. The results can lead to tailored treatment and individual follow-up for each patient with sarcoidosis.",[71],"Sarcoidosis","2026-03-05",{"date":74,"type":75},"2026-03-06","ACTUAL",{"date":77,"type":75},"2024-07-07",{"date":79,"type":67},"2034-12-31",{"name":5,"class":6},1]